Your browser doesn't support javascript.
loading
Electronic medical records can be used to emulate target trials of sustained treatment strategies.
Danaei, Goodarz; García Rodríguez, Luis Alberto; Cantero, Oscar Fernández; Logan, Roger W; Hernán, Miguel A.
Afiliación
  • Danaei G; Department of Global Health and Population, Harvard TH Chan School of Public Health, Boston, MA, USA; Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA. Electronic address: gdanaei@hsph.harvard.edu.
  • García Rodríguez LA; Centro Español de Investigación Farmacoepidemiológica, Madrid, Spain.
  • Cantero OF; Centro Español de Investigación Farmacoepidemiológica, Madrid, Spain.
  • Logan RW; Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA.
  • Hernán MA; Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA; Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA, USA; Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA, USA.
J Clin Epidemiol ; 96: 12-22, 2018 04.
Article en En | MEDLINE | ID: mdl-29203418
ABSTRACT

OBJECTIVE:

To emulate three target trials single treatment vs. no treatment, joint treatment vs. no treatment, and head-to-head comparison of two treatments, we explain how to estimate the observational analogs of intention-to-treat and per-protocol effects, using hazard ratios and survival curves. For per-protocol effects, we describe two methods for adherence adjustment via inverse-probability weighting. STUDY DESIGN AND

SETTING:

Prospective observational study using electronic medical records of individuals aged 55-84 with coronary heart disease from >500 practices in the United Kingdom between 2000 and 2010.

RESULTS:

The intention-to-treat mortality hazard ratio (95% confidence interval) was 0.90 (0.84, 0.97) for statins vs. no treatment, 0.88 (0.73, 1.06) for statins plus antihypertensives vs. no treatment, and 0.91 (0.77, 1.06) for atorvastatin vs. simvastatin. When censoring nonadherent person-times, the per-protocol mortality hazard ratio was 0.74 (0.64, 0.85) for statins vs. no treatment, 0.55 (0.35, 0.87) for statins plus antihypertensives vs. no treatment, and 1.13 (0.88, 1.45) for atorvastatin vs. simvastatin. We estimated per-protocol hazard ratios for a 5-year treatment using different dose-response marginal structural models and standardized survival curves for each target trial using intention-to-treat and per-protocol analyses.

CONCLUSION:

When randomized trials are not available or feasible, observational analyses can emulate a variety of target trials.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 6_ODS3_enfermedades_notrasmisibles Problema de salud: 1_sistemas_informacao_saude / 6_cardiovascular_diseases / 6_ischemic_heart_disease Asunto principal: Inhibidores de Hidroximetilglutaril-CoA Reductasas / Enfermedad Coronaria / Antihipertensivos Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Prognostic_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Clin Epidemiol Asunto de la revista: EPIDEMIOLOGIA Año: 2018 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 6_ODS3_enfermedades_notrasmisibles Problema de salud: 1_sistemas_informacao_saude / 6_cardiovascular_diseases / 6_ischemic_heart_disease Asunto principal: Inhibidores de Hidroximetilglutaril-CoA Reductasas / Enfermedad Coronaria / Antihipertensivos Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Prognostic_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Clin Epidemiol Asunto de la revista: EPIDEMIOLOGIA Año: 2018 Tipo del documento: Article
...